PR Newswire

Thailand Newswire x PR Newswire

PR Newswire - /DISREGARD RELEASE: Celltrion USA/

CISION PR Newswire - ซิชั่น พีอาร์ นิวส์ไวร์


Like This Page?

We are advised by Celltrion USA that journalists and other readers should disregard the news release, Celltrion USA partners with Express Scripts and Cigna Healthcare to expand access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab on their medical benefit formulary, issued 28-Aug-2024 over PR Newswire.


Source : CISION PR Newswire - /DISREGARD RELEASE: Celltrion USA/ https://www.prnasia.com/story/archive/4492006_CN92006_0

The information provided in this article was created by CISION PR Newswire, our news partner. The author's opinions and the content shared on this page are their own and may not necessarily represent the perspectives of Thailand Newswire.


Comment :